エボラ出血熱の治療薬とワクチンの世界市場

エボラ出血熱の治療薬とワクチンの世界市場は2030年までに1億4,550万米ドルに達する見込み

2024年に3,620万米ドルと推定されるエボラ出血熱の治療薬とワクチンの世界市場は、2024年から2030年にかけてCAGR 26.1%で成長し、2030年には1億4,550万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるZMappは、CAGR23.6%を記録し、分析期間終了時には4,700万米ドルに達すると予測されます。ファビピラビルセグメントの成長率は、分析期間中CAGR 25.9％と推定されます。

米国市場は990万米ドルと推定、中国はCAGR34.0％で成長すると予測

米国のエボラ出血熱の治療薬とワクチン市場は2024年に990万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR34.0％を牽引し、2030年までに3,510万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ21.3％と23.3％と予測されています。欧州では、ドイツがCAGR 21.9%で成長すると予測されています。

世界のエボラ出血熱の治療薬とワクチン市場- 主要動向と促進要因のまとめ

なぜエボラ出血熱の治療薬とワクチンが将来の感染症発生や世界の健康危機の予防に不可欠なのか？

エボラ出血熱の治療薬とワクチンは、世界で最も危険で致死率の高いウイルス性疾患に対する世界の対応戦略の中心的存在です。エボラウイルスは、出血熱を引き起こし、死亡率が50％を超えることがあることで知られており、特にヘルスケア・インフラが脆弱な地域において、公衆衛生に深刻な脅威をもたらしています。エボラ出血熱の流行は歴史的に中央アフリカと西アフリカに限られていたが、世界の旅行や貿易の相互接続により、国境を越えた感染のリスクが高まっており、効果的な治療薬とワクチンの開発と配備が国際的な緊急課題となっています。1万1,000人以上の命を奪った前例のない2014年から2016年にかけての西アフリカの大流行は、強力な医療対策の切実な必要性を強調し、エボラ出血熱に特化した治療薬やワクチンの研究開発・承認を加速させるための世界の大きな取り組みのきっかけとなりました。モノクローナル抗体（インマゼブやエバンガなど）やエルベボのようなワクチンは、それ以来、アウトブレイクを管理する最前線のツールとして登場し、生存率を劇的に向上させ、より効果的な封じ込めを可能にしています。これらのツールは命を救うだけでなく、感染を減らし、最前線の医療従事者を守り、流行緊急時の社会的信頼を回復するためにも役立っています。エボラ出血熱が人獣共通感染症の脅威として繰り返されている現在、将来の健康危機を予防し、流行への備えを維持するためには、医薬品とワクチンへの持続的な投資が不可欠です。

科学の進歩と緊急対応枠組みは、エボラ治療薬のイノベーションをどのように促進しているのか？

エボラ出血熱の治療薬とワクチンの状況は、最先端の科学的イノベーション、世界の協力体制、そして発生した緊急事態に対応するために構築された官民パートナーシップに後押しされ、急速に発展してきました。当初は、エボラ出血熱の流行が散発的で地理的に限定されていたことが妨げとなっていたが、西アフリカでの流行後、研究開発努力はかつてない勢いを増し、臨床試験の加速化と緊急使用認可につながりました。インマゼブ（3種類の抗体のカクテル）やエバンガ（単一抗体）などのモノクローナル抗体治療は、臨床現場においてウイルスを中和し生存率を向上させる顕著な効果を示しました。ワクチンの面では、組換え型水疱性口内炎ウイルスベースのErveboワクチンが画期的で、1回投与で予防効果を発揮し、コンゴ民主共和国で発生したアウトブレイク時のリングワクチン接種戦略への導入に成功しています。アデノウイルスベクターやmRNAプラットフォームを用いた新規ワクチン候補も開発中で、COVID-19ワクチン開発の教訓を生かし、より迅速な製造と幅広い防御を可能にしています。さらに、リアルタイムのゲノム・サーベイランスとモバイル診断プラットフォームは、より的を絞った治療アプローチと迅速なアウトブレイク特定を可能にしています。WHO、CEPI、GAVIなどの組織は、世界の対応枠組みの調整、ワクチン備蓄の促進、開発促進のための資金提供において極めて重要な役割を果たしています。このような進歩は、エボラ出血熱との闘いにおいて、持続的な科学的革新、柔軟な規制の仕組み、協調的な対応戦略の重要性を強調しています。

なぜ地理的、経済的、インフラ的要因がエボラ出血熱の治療薬とワクチンの配備に影響を与えるのか？

エボラ出血熱の治療薬とワクチンの配備は、地域の保健インフラ、経済能力、物流準備によって大きく左右されます。コンゴ民主共和国、ギニア、ウガンダのような国々は、何度も大流行を経験しており、緊急対応のために国際援助や保健パートナーシップに大きく依存しています。これらの地域では、脆弱な保健システム、限られたコールドチェーン能力、遠隔地の住民、政情不安などが、救命活動の迅速な提供や実施をしばしば複雑にしています。承認されたワクチンや治療法が利用可能であるにもかかわらず、誤った情報、ワクチン接種のためらい、文化的抵抗、不十分なサーベイランスといった課題が、ワクチン摂取や有効性の妨げとなっています。これとは対照的に、高所得国には、必要であれば対策を迅速に展開できる技術力と保健インフラがあるが、リスクプロファイルが低いため、エボラ出血熱に特化した資源を優先しないことが多いです。したがって、こうした格差を埋めるためには、ワクチンの公平性を高めるCOVAXのような取り組みや、現地での生産と流通を増やすことを目的とした地域製造パートナーシップを通じた国際協力が不可欠です。さらに、現地のヘルスケアワーカーを訓練し、疾病監視ネットワークを強化し、地域社会の関与に投資することは、効果的な展開に不可欠な要素です。このような地域的なニュアンスの違いは、医療技術革新だけでは不十分であり、ロジスティクスの調整、社会・政治的戦略、医療システムの強化が、エボラ出血熱の治療薬とワクチンの供給と利用を成功させるために同様に重要であることを示しています。

エボラ出血熱の治療薬とワクチン市場の成長を促進する主な要因は？

エボラ出血熱の治療薬とワクチン市場の成長は、繰り返し発生するアウトブレイク、世界ヘルスセキュリティの優先事項の高まり、政府や国際保健機関からの戦略的資金提供の組み合わせによってもたらされます。野生生物にエボラウイルスのリザーバーが存在し、動物からヒトへの感染が頻発していることから、継続的な警戒と備えが必要であることが浮き彫りになっています。この緊急性は、米国バイオメディカル先端研究開発局（BARDA）、疫病対策イノベーション連合（CEPI）、世界保健機関（WHO）などの組織による研究開発への持続的な投資につながっており、これらの組織はいずれもエボラ治療薬やワクチンの開発、調達、配布に積極的に資金を提供しています。この市場は、抗体療法やベクターベースのワクチンのスケーラブルな生産を可能にする生物製剤製造の進歩によってさらに推進されています。また、COVID-19の大流行は、強固なワクチン・プラットフォームとパンデミックへの備えの必要性に対する世界の認識を高め、迅速な開発と集団予防接種戦略の成功を示すことで、間接的にエボラ対策パイプラインに利益をもたらしています。さらに、戦略的備蓄プログラムや国際援助パッケージは、特にリスクの高い地域におけるエボラ出血熱への介入に対する基本的な需要を確保しています。製薬会社は、繰り返し需要が発生する可能性を認識し、迅速な対応製造と規制上の機敏性のための能力を拡大しています。これらの要因が相まって、より弾力性があり、対応力があり、商業的に実行可能なエボラ出血熱の治療薬とワクチン市場が形成されつつあります。

セグメント

新薬タイプ（ZMapp, Favipiravir, Gs-5734, Tkm-Ebola, Avi-7537）;ワクチンタイプ（Cad3-Zebov, Rvsv-Zebov,その他のワクチンタイプ）;菌株タイプ（ザイール,スーダン,タイフォレスト,レストン,ブンディブギョウイルス）;エンドユーザー（病院＆クリニック,外来手術センター,その他のエンドユーザー）

調査対象企業の例（注目の44社）

• AIM ImmunoTech
• Arbutus Biopharma Corporation
• Bavarian Nordic A/S
• BioCryst Pharmaceuticals, Inc.
• Chimerix, Inc.
• Emergent BioSolutions Inc.
• Fujifilm Toyama Chemical Co., Ltd.
• GeneOne Life Sciences, Inc.
• GeoVax Labs, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• IMV Inc.
• Johnson & Johnson
• Mapp Biopharmaceutical, Inc.
• NanoViricides, Inc.
• NewLink Genetics Corporation
• Novavax, Inc.
• Peptineo LLC
• Regeneron Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Ebola Drugs and Vaccines Market to Reach US$145.5 Million by 2030

The global market for Ebola Drugs and Vaccines estimated at US$36.2 Million in the year 2024, is expected to reach US$145.5 Million by 2030, growing at a CAGR of 26.1% over the analysis period 2024-2030. ZMapp, one of the segments analyzed in the report, is expected to record a 23.6% CAGR and reach US$47.0 Million by the end of the analysis period. Growth in the Favipiravir segment is estimated at 25.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.9 Million While China is Forecast to Grow at 34.0% CAGR

The Ebola Drugs and Vaccines market in the U.S. is estimated at US$9.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$35.1 Million by the year 2030 trailing a CAGR of 34.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 21.3% and 23.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 21.9% CAGR.

Global Ebola Drugs and Vaccines Market - Key Trends & Drivers Summarized

Why Are Ebola Drugs and Vaccines Vital in Preventing Future Outbreaks and Global Health Crises?

Ebola drugs and vaccines are central to the global response strategy against one of the world’s most dangerous and highly fatal viral diseases. The Ebola virus, known for causing hemorrhagic fever and having mortality rates that can exceed 50%, poses a serious threat to public health, especially in regions with fragile healthcare infrastructure. While outbreaks have historically been confined to Central and West Africa, the interconnectedness of global travel and trade elevates the risk of cross-border transmission, making the development and deployment of effective therapeutics and vaccines a matter of international urgency. The unprecedented 2014-2016 West African outbreak, which claimed over 11,000 lives, underscored the dire need for robust medical countermeasures and catalyzed major global efforts to accelerate research, development, and approval of Ebola-specific drugs and vaccines. Treatments like monoclonal antibodies (e.g., Inmazeb and Ebanga) and vaccines such as Ervebo have since emerged as frontline tools in managing outbreaks, drastically improving survival rates and enabling more effective containment. These tools are not only life-saving but also instrumental in reducing transmission, protecting frontline health workers, and restoring public confidence during epidemic emergencies. With Ebola now considered a recurring zoonotic threat, sustained investment in drugs and vaccines is essential to prevent future health crises and maintain epidemic preparedness.

How Are Scientific Advancements and Emergency Response Frameworks Driving Innovation in Ebola Therapeutics?

The Ebola drug and vaccine landscape has rapidly evolved, propelled by cutting-edge scientific innovation, global collaboration, and public-private partnerships forged in response to outbreak emergencies. Initially hindered by the sporadic and geographically limited nature of Ebola outbreaks, R&D efforts gained unprecedented momentum following the West African epidemic, leading to accelerated clinical trials and emergency use authorizations. Monoclonal antibody treatments such as Inmazeb (a cocktail of three antibodies) and Ebanga (a single antibody) have demonstrated significant efficacy in neutralizing the virus and improving survival in clinical settings. On the vaccine front, the recombinant vesicular stomatitis virus-based Ervebo vaccine has been a game-changer, providing single-dose protection and being successfully deployed in ring vaccination strategies during outbreaks in the Democratic Republic of Congo. Novel vaccine candidates using adenovirus vectors and mRNA platforms are also under development, drawing on lessons from COVID-19 vaccine development to enable faster production and broader protection. Additionally, real-time genomic surveillance and mobile diagnostic platforms are enabling more targeted therapeutic approaches and quicker outbreak identification. Organizations such as the WHO, CEPI, and GAVI play pivotal roles in coordinating global response frameworks, facilitating vaccine stockpiling, and funding accelerated development efforts. These advancements underscore the importance of sustained scientific innovation, flexible regulatory mechanisms, and coordinated response strategies in the fight against Ebola.

Why Do Geographic, Economic, and Infrastructural Factors Influence Ebola Drug and Vaccine Deployment?

The deployment of Ebola drugs and vaccines is profoundly shaped by regional health infrastructure, economic capacity, and logistical readiness, with sub-Saharan Africa remaining the epicenter of disease burden and intervention efforts. Countries such as the Democratic Republic of Congo, Guinea, and Uganda have experienced multiple outbreaks and rely heavily on international aid and health partnerships for emergency response. In these areas, fragile health systems, limited cold chain capabilities, remote populations, and political instability often complicate rapid delivery and administration of life-saving interventions. Despite the availability of approved vaccines and treatments, challenges such as misinformation, vaccine hesitancy, cultural resistance, and inadequate surveillance can hinder uptake and effectiveness. In contrast, high-income countries possess the technological capacity and health infrastructure to deploy countermeasures rapidly if needed, but often deprioritize Ebola-specific resources due to lower risk profiles. International cooperation is therefore essential to bridge these disparities-through initiatives such as COVAX for vaccine equity and regional manufacturing partnerships aimed at increasing local production and distribution. Moreover, training local healthcare workers, strengthening disease monitoring networks, and investing in community engagement are vital components of effective deployment. These regional nuances demonstrate that medical innovation alone is insufficient-logistical coordination, socio-political strategy, and health system strengthening are equally critical in ensuring successful delivery and utilization of Ebola drugs and vaccines.

What Are the Key Drivers Fueling Growth in the Ebola Drugs and Vaccines Market?

The growth in the Ebola drugs and vaccines market is driven by a combination of recurring outbreaks, heightened global health security priorities, and strategic funding from governments and international health bodies. The persistence of Ebola virus reservoirs in wildlife and the increasing frequency of spillover events from animals to humans highlight the need for continuous vigilance and preparedness. This urgency has translated into sustained investment in R&D from organizations such as the U.S. Biomedical Advanced Research and Development Authority (BARDA), the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), all of which are actively funding the development, procurement, and distribution of Ebola therapeutics and vaccines. The market is further propelled by advancements in biologics manufacturing, enabling scalable production of antibody therapies and vector-based vaccines. The COVID-19 pandemic has also increased global awareness about the necessity of robust vaccine platforms and pandemic readiness, indirectly benefiting the Ebola countermeasures pipeline by showcasing the success of rapid development and mass immunization strategies. Additionally, strategic stockpiling programs and international aid packages ensure a baseline demand for Ebola interventions, particularly in at-risk regions. Pharmaceutical companies, recognizing the potential for recurring demand, are expanding capabilities for rapid response manufacturing and regulatory agility. Together, these factors are driving a more resilient, responsive, and commercially viable market for Ebola drugs and vaccines-one that is increasingly aligned with the broader goal of global health security.

SCOPE OF STUDY:

The report analyzes the Ebola Drugs and Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Novel Drug Type (ZMapp, Favipiravir, Gs-5734, Tkm-Ebola, Avi-7537); Vaccine Type (Cad3-Zebov, Rvsv-Zebov, Other Vaccine Types); Strain Type (Zaire, Sudan, Tai Forest, Reston, Bundibugyo Virus); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AIM ImmunoTech
• Arbutus Biopharma Corporation
• Bavarian Nordic A/S
• BioCryst Pharmaceuticals, Inc.
• Chimerix, Inc.
• Emergent BioSolutions Inc.
• Fujifilm Toyama Chemical Co., Ltd.
• GeneOne Life Sciences, Inc.
• GeoVax Labs, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• IMV Inc.
• Johnson & Johnson
• Mapp Biopharmaceutical, Inc.
• NanoViricides, Inc.
• NewLink Genetics Corporation
• Novavax, Inc.
• Peptineo LLC
• Regeneron Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Ebola Drugs and Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Global Health Security Agendas Throw the Spotlight on Ebola Drug and Vaccine Development
  • Recurrent Outbreaks in Central and West Africa Propel Demand for Rapid Deployment Therapeutics
  • Here's How Emergency Use Authorizations Accelerate Market Entry of Experimental Ebola Solutions
  • WHO Prequalification of Ebola Vaccines Strengthens Procurement by Global Health Bodies
  • Growth in Zoonotic Surveillance Expands Addressable Market for Preventive and Post-Exposure Solutions
  • Here's the Story: Multilateral Funding and NGO Partnerships Fuel Access in Resource-Constrained Areas
  • Innovations in Viral Vector and RNA Vaccine Platforms Enhance Rapid Response Capability
  • Cold-Chain Optimization Initiatives Improve Last-Mile Delivery of Thermally Sensitive Vaccines
  • Dual-Use Vaccine Development Models Create Synergies With Other Hemorrhagic Fever Programs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ebola Drugs and Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Ebola Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for ZMapp by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for ZMapp by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for ZMapp by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Favipiravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Favipiravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Favipiravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Gs-5734 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Gs-5734 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Gs-5734 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Tkm-Ebola by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Tkm-Ebola by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Tkm-Ebola by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Avi-7537 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Avi-7537 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Avi-7537 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Sudan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Sudan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Sudan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Tai Forest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Tai Forest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Tai Forest by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Reston by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Reston by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Reston by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Bundibugyo Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Bundibugyo Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Bundibugyo Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Zaire by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Zaire by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Zaire by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Cad3-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Cad3-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Cad3-Zebov by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Rvsv-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Rvsv-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Rvsv-Zebov by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• JAPAN
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• CHINA
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• EUROPE
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Ebola Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• FRANCE
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• GERMANY
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• INDIA
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Ebola Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Ebola Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
• AFRICA
  • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030

IV. COMPETITION